Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of the Safety and Immunologic Biomarker After Conversion From Calcineurin Inhibitor to Rapamune in Stable Renal Transplant Recipient

NCT01592253 is registered in ClinicalTrials.gov with Seoul St. Mary's Hospital as lead sponsor.

NCT NCT01592253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01592253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of the Safety and Immunologic Biomarker After Conversion From Calcineurin Inhibitor to Rapamune in Stable Renal Transplant Recipient
Lead sponsor
Seoul St. Mary's Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2012
Completion date
December 31, 2013
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute rejection of renal transplant